% | $
Quotes you view appear here for quick access.

Celldex Therapeutics, Inc. Message Board

  • weightbayou weightbayou Dec 14, 2013 2:53 PM Flag

    Huge news concerning CDX-301

    Maybe this was posted already. I did not know. cdx-301 moves ahead relentlessly.

    In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy
    This study is currently recruiting participants.
    Verified December 2013 by Mount Sinai School of Medicine
    Joshua Brody
    Information provided by (Responsible Party):
    Joshua Brody, Mount Sinai School of Medicine
    Low-Grade B-cell Lymphoma
    Drug: rhuFlt3L/CDX-301
    Drug: Poly-ICLC

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • December 10, 2013
      Celldex's CDX-301 in Combination with Mozobil(R) Increases Hematopoietic Stem Cell Mobilization and Results in Improved Transplantation of Mobilized Cells in Preclinical Studies; Results Presented at ASH 2013

      HAMPTON, N.J., Dec. 10, 2013 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today positive results from a preclinical combination study of CDX-301 (FMS-like tyrosine kinase-3 ligand or Flt3L) and Mozobil® (Plerixafor injection, formerly AMD3100) demonstrating that the combination of these agents significantly increases hematopoietic stem cell mobilization in mice. The data support future clinical development of CDX-301 and demonstrate a novel potent cell mobilization regimen combining CDX-301 and Mozobil®, which may have significant potential for use in autologous and allogeneic hematopoietic stem cell transplantation. Results were presented in an oral session entitled "FLT3L and AMD3100 Combination Increases Hematopoietic Stem Cell Mobilization and Leads to Improved Transplantation Outcome" on Tuesday, December 10, 2013 at 7:30 am CT at the American Society of Hematology 55th Annual Meeting and Exposition (ASH). The studies were conducted in collaboration with Jianhua Yu, PhD, and Steven Devine, MD, and were presented by Shun He, PhD, all of The Ohio State University.

      "We need novel interventions to advance hematopoietic stem cell mobilization techniques and transplantation, and based on our studies to date, this could be a promising alternative approach for these patients," said Steven Devine, MD, Professor of Internal Medicine and Director, Blood and Marrow Transplant Program, The Ohio State University Comprehensive Cancer Center.

      "The data presented today further demonstrate the potential for CDX-301 to improve both autologous and allogeneic hematopoietic stem cell transplantation and, importantly, show the ability for CDX-301 to combine effectively with other cell mobilization agents," said Tibor Keler, PhD, Sen

    • Looks like the trial started up this month with a completion date of 2016.

3.79+0.01(+0.26%)1:11 PMEDT